- Home
- BIVI vs HUBC Comparison
BIVI vs HUBC Comparison
Compare BIVI & HUBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- HUBC
- Stock Information
- Founded
- BIVI 2013
- HUBC 2017
- Country
- BIVI United States
- HUBC Israel
- Employees
- BIVI N/A
- HUBC N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- HUBC
- Sector
- BIVI Health Care
- HUBC
- Exchange
- BIVI Nasdaq
- HUBC Nasdaq
- Market Cap
- BIVI 18.8M
- HUBC N/A
- IPO Year
- BIVI N/A
- HUBC N/A
- Fundamental
- Price
- BIVI $0.78
- HUBC $3.09
- Analyst Decision
- BIVI Strong Buy
- HUBC
- Analyst Count
- BIVI 1
- HUBC 0
- Target Price
- BIVI $30.00
- HUBC N/A
- AVG Volume (30 Days)
- BIVI 249.0K
- HUBC 175.5K
- Earning Date
- BIVI 05-13-2025
- HUBC 12-13-2024
- Dividend Yield
- BIVI N/A
- HUBC N/A
- EPS Growth
- BIVI N/A
- HUBC N/A
- EPS
- BIVI N/A
- HUBC N/A
- Revenue
- BIVI N/A
- HUBC $33,357,000.00
- Revenue This Year
- BIVI N/A
- HUBC N/A
- Revenue Next Year
- BIVI N/A
- HUBC N/A
- P/E Ratio
- BIVI N/A
- HUBC N/A
- Revenue Growth
- BIVI N/A
- HUBC N/A
- 52 Week Low
- BIVI $0.76
- HUBC $2.65
- 52 Week High
- BIVI $7.50
- HUBC $21.70
- Technical
- Relative Strength Index (RSI)
- BIVI 30.49
- HUBC 34.90
- Support Level
- BIVI $0.80
- HUBC $2.65
- Resistance Level
- BIVI $1.00
- HUBC $3.72
- Average True Range (ATR)
- BIVI 0.11
- HUBC 0.69
- MACD
- BIVI -0.00
- HUBC -0.10
- Stochastic Oscillator
- BIVI 3.58
- HUBC 12.01
Stock Price Comparison Chart: BIVI vs HUBC
■ BIVI
■ HUBC
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.